- Not all genetic technologies used in veterinary medicine fall under the categories of “mRNA vaccines” or “mRNA gene therapies.” There are other terms to look out
- There are several DNA and RNA-based genetic technologies that have received USDA approval or conditional approval for use on chickens, cows, fish, and pigs
- The required labeling for meat, dairy and egg products is not transparent about possible exposure to DNA or RNA-based veterinary biologics
1. What Are the Different Terms Used for DNA or RNA-Based Veterinary Biologics?
Not all genetic technologies used in veterinary medicine fall under the categories of “mRNA vaccines” or “mRNA gene therapies.” There are other terms to look out for when it comes to genetic technologies for veterinary medicine. These terms also include:
- “RNA Particle Technology”
- “RNA Particle Platform”
- “DNA Vaccine”
- “DNA Immunostimulant”
- “Prescription Platform Product”
2. How Do DNA or RNA-Based Veterinary Biologics Work?
With SEQUIVITY’s RNA Particle Technology, a “gene of interest provides instructions” to the immune cells which “translate the sequence into proteins” that “act as antigens.” This triggers an immune response.
As for AgriLab’s ExactVac DNA technology, “the vaccine is produced by splicing a gene for a specific antigen” into “a bacterial plasmid” which “is then multiplied, purified and administered” for “delivery into target cells, where antigens produced by the plasmid elicit an immune response.”
Bayer’s Zelnate DNA immunostimulant is “made up of a special type of immunostimulatory DNA surrounded by a lipid carrier or liposome” which is then “engulfed by the animal’s immune cell” where the “liposome breaks down exposing the DNA” and the “pathogen-associated molecular pattern” of the DNA “attaches to the immune cell’s toll-like receptors triggering activation of the immune cell.”
3. Which Agency Approves Veterinary Biologics?
The USDA’s Animal and Plant Health Inspection Service (APHIS) and their Center for Veterinary Biologics is responsible for approving veterinary biological products including vaccines and DNA or RNA-based biologics. Here are the lists of the currently licensed veterinary biological products and biologics for aquatic animals.
4. Which DNA or RNA-Based Biologics Have Been Approved for Food Animals?
There are several DNA and RNA-based genetic technologies that have received USDA approval or conditional approval for use on chickens, cows, fish, and pigs as outlined below.
- Chickens
◦In September 2015, Harrisvaccines received a USDA conditional license for an RNA-based avian influenza vaccine. Harrisvaccines “employs their unique SirraVaxSM RNA Particle (RP) technology platform” which can be updated to match current and future avian flu strains.
In October 2015, Harrisvaccines was awarded a USDA stockpile contract of 48 million doses of their “pioneering RNA particle vaccine.” In November 2015, Merck acquired Harrisvaccines.
◦In November 2017, AgriLabs received USDA conditional approval for “the first DNA vaccine ever licensed for chickens” for avian flu using “AgriLabs’ ExactVac DNA technology with ENABL adjuvant.” In January 2018, Huvepharma acquired AgriLabs. Huvepharma’s DNA-based avian influenza vaccine has a conditional license on APHIS’s most recent list of approved veterinary biological products.
- Cows
◦Bayer’s Zelnate DNA Immunostimulant received USDA approval for use against bovine respiratory disease (BRD) in January 2014. Zelnate is the “first-of-its-kind” DNA immunostimulant that is a genetic technology rather than a vaccine or antibiotic. Bayer’s DNA immunostimulant is on APHIS’s most recent list of approved veterinary biological products.
- Fish
◦Elanco’s Apex IHN DNA vaccine for salmonids against Infectious Hematopoietic Necrosis Virus (IHNV) has received USDA approval and is on APHIS’s most recent list of licensed biologics for aquatic animals.
Elanco’s DNA technology uses “relevant genetic components of the virus” that are inserted into a plasmid and injected into the muscle, after which the plasmid “instructs cells to produce antigens, which initiate an immune response.”
- Pigs
◦In June 2014, Harrisvaccines became the first in the nation to receive USDA conditional licensing for their RNA-based PEDv vaccine for pigs. In November 2015, Merck acquired Harrisvaccines. Merck’s “RNA particle platform” for Coronavirus and Porcine Epidemic Diarrhea Vaccine (PEDv) has conditional approval by the USDA and this product has conditional licensing on APHIS’s most recent list of veterinary biological products.
◦In December 2017, AgriLabs received USDA approval for a DNA-based swine flu vaccine. In January 2018, Huvepharma acquired AgriLabs. Huvepharma’s ExactVac DNA-based swine flu vaccine is on APHIS’s most recent list of approved veterinary biological products.
◦In 2020, Huvepharma’s DNA-based vaccine platform for pigs received USDA approval as a “prescription platform product” so that the “manufacturer may update the gene insert in this vaccine under expedited procedures to respond to emerging needs.” Huvepharma’s DNA-based swine vaccine platform has conditional licensing as a prescription product on APHIS’s most recent list of approved veterinary biological products.
◦In 2020 and 2021, Merck’s Sequivity RNA vaccines for strains of swine influenza, which use “RNA particle technology,” were approved by the USDA and are on APHIS’s most recent list of approved veterinary biological products.
◦Also in 2021, Merck’s RNA particle technology, for use as a “prescription platform product,” was conditionally approved by the USDA and has conditional licensing on APHIS’s most recent list of veterinary biological products.
5. Is There Ongoing Research Into DNA or RNA-Based Veterinary Biologics?
There are a number of ongoing studies on DNA and RNA-based genetic technologies for veterinary medicine, as outlined below.
- Bayer Partners with BioNTech to Develop mRNA Vaccines, Drugs for Animal Health, May 2016
- Development of a Self-amplifying mRNA Vaccine for African Swine Fever and Classical Swine Fever, Start Date: Jun 1, 2021, End Date: May 31, 2024
- Development of mRNA-based Vaccines for Heterosubtypic Protection Against Infectious Bronchitis and Infectious Laryngotracheitis Viruses, Start Date: Oct 1, 2021, End Date: Sep 30, 2023
- mRNA Vaccine Development for Emerging Animal and Zoonotic Diseases, February 2022
- Novel mRNA Vaccine Technology for Prevention of Bovine Respiratory Syncytial Virus, Start Date Oct 1, 2021, End Date Sep 30, 2026
- Novel Vaccine Technologies in Veterinary Medicine: A Herald to Human Medicine Vaccines, April 2021
- Vaccines to Reduce Salmonella Infantis in Chickens, Start Date: Sep 1, 2022, End Date: Oct 1, 2024
6. Is It Possible for mRNA Vaccines in Livestock to Contaminate Meat, Dairy or Egg Products?
According to a recent Epoch Times report, a 2014 USDA presentation on Vaccination for Contagious Diseases states that food animals receiving vaccines are subject to “mandatory withdrawal periods prior to slaughter for human consumption. Animals may not be sent to market until the withdrawal time has elapsed.
During the mandatory withdrawal time vaccinated animals or products from vaccinated animals may not enter the food chain. The withdrawal time is determined by the country in which the vaccine is licensed and stated in the product license.” As the Epoch Times report notes, the USDA recognizes that there must be a waiting time between vaccination and slaughter for human consumption due to risks of contaminating the food supply.
The USDA presentation does not, however, acknowledge DNA or RNA-based biologics, but the same standard of waiting times likely applies, as evidenced by Merck’s RNA vaccine for pigs, which states “Do not vaccinate within 21 days before slaughter.” However, Dr. Peter McCullough notes that mRNA technology “is far more durable than we ever could’ve imagined. It lasts in the human body for months unchanged.”
Therefore, even with standard wait times, Dr. McCullough believes it is conceivable that mRNA technology administered to food animals could contaminate the food supply. With that said, the Epoch Times report found “zero peer-reviewed studies looking into the transmissibility of mRNA vaccines from livestock to humans via either milk or meat.”
Dr. Peter McCullough has warned that developers of novel vaccine technologies for veterinary medicine are “blinded with infatuation for molecular biology and have lost sight of biological product safety in the food supply” adding that they have failed to acknowledge the “possibility of collateral impact to humans.”
In addition, Dr. McCullough has raised concerns regarding transmissibility based on a recent study which loaded cow’s milk with mRNA, and by consuming the milk, mice were successfully administered a Covid vaccine.
Dr. McCullough points out the “considerable ethical issues” this research presents, with a large segment of the public having “strong objections to mRNA in the food supply, particularly if it was done surreptitiously or with minimal labelling/warnings.”
7. Are There Labeling Requirements for Meats, Dairy or Eggs That May Have Been Contaminated by DNA or RNA-Based Veterinary Biologics?
The required labeling for meat, dairy and egg products is not transparent about possible exposure to DNA or RNA-based veterinary biologics. The USDA does, however, require “Bioengineered” labeling for foods that “contain detectable genetic material that has been modified through certain lab techniques and cannot be created through conventional breeding or found in nature.”
It is unclear whether the USDA’s testing process for “detectable genetic material” is capable of picking up traces of genetic material from biologics used in veterinary medicine.
Moreover, the USDA’s “Organic” labeling does appear to permit vaccines for livestock used for meat, dairy and eggs, though the requirements state that animals must not be given hormones or antibiotics. A 2013 Agricultural Marketing Service document states that “organic livestock must be: – Produced without genetic engineering.” However, the same document goes on to say that “Only a few drugs, such as vaccines, are allowed” for organically raised livestock.
Furthermore, in many cases, labeling is not clear about the country from which meats originate. Country of Origin Labeling (COOL) requirements were dropped for beef and pork in 2016. COOL requirements remain in place for lamb, goat, chicken, and fish. Additionally, USDA regulations on meat, poultry and eggs have enabled “Product of USA” labeling for animals born and raised in other countries and only processed in the U.S.
However, in March 2023, the USDA proposed a new rule to restrict labeling for “Product of USA” or “Made in the USA” to be used on “meat, poultry and egg products only when they are derived from animals born, raised, slaughtered and processed in the United States.”
8. Which Organizations Are Behind This Agenda?
According to a Corey’s Digs report, Codex Alimentarius was established by the UN’s Food and Agriculture Organization (FAO) and the WHO, for “the sole purpose of setting the standards and guidelines for all food that is consumed by human beings.”
The report states that Codex does not have the authority to make laws, “so the 189 country members, 20 of which are heads of the various committees, take these ‘standards’ and create regulations and laws in their respective country. The USDA, for example, is a driving force for not only adhering to the standards, but making certain other countries follow in lock step as well.”
Codex Alimentarius plays “a key role” in the implementation of new technologies within food standards, including “genetic editing” and “nanotechnology applications in the food sector” as well as “alternative food proteins.”
9. What Are Lawmakers, Producers and Concerned Citizens Doing to Protect Against Contamination of the Food Supply From mRNA Vaccines?
Lawmakers have proposed legislation in Arizona, Idaho, Missouri, South Carolina, Tennessee, and Texas to prohibit mRNA in meats or to require disclosure in food labeling. While legislation in Missouri and Idaho failed, efforts to block mRNA vaccines in livestock remain ongoing in other states.
A trade group, known as The Beef Initiative, has pledged that their Beef Box producers will not “use any mRNA vaccines in their livestock.” Over 100 producers are partnered with The Beef Initiative and can be found here.
Attorney Tom Renz has spearheaded the movement by states for transparency and disclosure of mRNA gene therapies in the food supply. Renz helped to draft Missouri’s HB1169. Naomi Wolf of Daily Clout is also promoting the cause. Doctor Peter McCullough has raised awareness on the issue of genetic technologies used in veterinary medicine and the potential dangers to the food supply in recent interviews and on substack publications.
10. What Can the Public Do about It?
Stay informed and inform others by sharing this information. Additional resources on this topic are listed below. Support lawmakers and advocacy groups pushing for transparency and blocking DNA or RNA-based biologics from entering the food supply. Know what’s in your food and who is producing it.
Buy from producers that have pledged to never use DNA or RNA-based genetic technologies, such as The Beef Initiative. Corey’s Digs has also published an excellent resource for finding high-quality foods as well as an incredible source for US Prime and High Choice Beef.
Editor’s Note: Prepper All Naturals has vowed to never sell long-term storage beef tainted by mRNA vaccines. Take advantage of 15% off at checkout with promo code JDR.
Bypass Big Tech Censors
Why Bullion Beats Numismatics and Collectible for Your Safe or IRA
Precious metals continue to attract Americans seeking reliable ways to protect their wealth amid inflation, geopolitical risks, and stock market swings. Whether stored in a home safe or held inside a self-directed IRA, physical gold and silver deliver tangible value that paper or digital assets often lack. Yet investors must choose carefully between bullion—pure bars and coins valued mainly for their metal content—and numismatics or collectibles, where rarity, history, and collector demand heavily influence pricing.
Advisor Bullion serves as a dependable source for straightforward, high-quality bullion. The company specializes in physical gold, silver, platinum, and palladium, emphasizing transparent pricing and products that deliver maximum metal content for every dollar spent. This approach makes it ideal for both personal holdings and retirement accounts.
Bullion consists of refined precious metals in standard forms like one-ounce coins (American Gold Eagles, Silver Eagles, Canadian Maple Leafs) or bars. Their value tracks closely to the current spot price of the metal. A typical gold bullion coin trades near the live gold spot price plus a small premium. This structure keeps costs clear and predictable.
Numismatic coins and collectibles add substantial value from factors such as age, rarity, minting errors, or historical significance. A pre-1933 U.S. gold coin or graded proof piece can carry premiums of 30%, 50%, or even 200% above melt value. While this appeals to hobbyists, it creates complexity. Pricing depends on subjective grading, collector trends, and auction results instead of daily spot prices.
For investors focused on wealth preservation and retirement security rather than building a collection, bullion often delivers better results.
Lower Costs and Better Liquidity for Home Storage
When keeping metals in a home safe or private vault, liquidity and efficiency count. Bullion offers clear benefits:
- You acquire more actual gold or silver per dollar invested. Numismatics divert a large share of your money into rarity premiums and massive sales commission, reducing your metal exposure.
- Selling bullion involves tight bid-ask spreads, so you recover nearly full spot value with minimal fees. Collectibles require finding the right buyer and may sell at a discount if demand for that specific item weakens.
- Bullion prices remain transparent and update with global spot markets. You can track gold near current levels or silver accordingly and know exactly where your holdings stand. Numismatic values are priced by the Gold IRA companies with hefty margins applied.
- Standardized coins and bars store efficiently and divide easily for partial sales. Rare coins often need protective slabs and controlled conditions, adding hassle and expense.
- Bullion enjoys worldwide acceptance. A 1-oz Gold Maple Leaf or Silver Eagle sells quickly to dealers anywhere. Niche numismatic pieces may appeal only to limited buyers, slowing liquidation when speed matters.
In times when quick access to value becomes important, bullion’s simplicity stands out.
Stronger Fit for Precious Metals IRAs
Precious metals IRAs continue gaining traction as investors diversify retirement portfolios beyond stocks and bonds. IRS rules permit certain bullion products in self-directed IRAs if they meet purity standards (.995 fine for gold, .999 for silver) and are held by an approved custodian. Eligible items include American Gold and Silver Eagles plus many generic bars and rounds from recognized mints.
Numismatic and most collectible coins generally face heavy scrutiny from custodians due to valuation disputes and elevated markups. These higher premiums mean less actual metal ends up working inside the account.
Bullion avoids these issues. Its value links directly to verifiable spot prices, which simplifies reporting and lowers the risk of regulatory challenges. More of your IRA contribution purchases real metal instead of dealer profits or speculative upside. Over time, owning additional ounces that appreciate with the metal itself can create meaningful outperformance compared with high-premium alternatives that deliver fewer ounces.
Regulatory guidance from the CFTC and state securities offices repeatedly cautions against aggressive sales of expensive numismatics or “semi-numismatic” coins for IRAs. For retirement planning, transparent bullion from established providers reduces risk and aligns better with long-term goals.
How to Get Started with Bullion
Begin by clarifying your goals. Are you protecting savings in a safe, or moving part of a retirement account into a precious metals IRA? Focus on the number of ounces you can acquire at current prices rather than chasing marked-up collectibles.
Diversify sensibly: use gold for core preservation and silver for its blend of industrial and monetary qualities. Mix coins for easier divisibility with bars for lower per-ounce costs on larger buys. Arrange secure storage—whether at home with proper insurance or through professional facilities.
As economic uncertainties linger and faith in conventional assets erodes, bullion continues proving its worth as a dependable store of value. Its direct approach avoids the hype that sometimes surrounds collectible markets and keeps the focus on the metal itself.
For investors prepared to strengthen their portfolios, Advisor Bullion supplies the expertise and selection needed to acquire high-quality bullion efficiently. Whether building personal holdings or integrating metals into an IRA, their emphasis on transparent, investment-grade products helps secure more ounces today that support greater financial security tomorrow. In a complicated financial landscape, bullion’s clarity and reliability make it the smarter foundation for protecting what matters most.